Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785798 · ClinicalTrials.gov registry record · Phase 1
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00785798: Clinical Trial Phase 1 study, sponsored by Yale University.
NCT00785798 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00785798, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
Primary Outcome
number of patients responding
Interventions
- DRUG Vorinostat
- DRUG Pegylated Liposomal Doxorubicin (PLD), Doxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Why NCT00785798 stopped before completion
NCT00785798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT00785798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00785798 about?
NCT00785798 is a clinical study titled "Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas". The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
What is the current status of trial NCT00785798?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00785798?
The interventions under investigation include: Vorinostat (DRUG), Pegylated Liposomal Doxorubicin (PLD), Doxil (DRUG).
Who is sponsoring clinical trial NCT00785798?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00785798's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia